Detection of Patients With Abnormal Water Distribution Based on Bioelectrical Impedance Analysis (BIA)
NCT ID: NCT01481311
Last Updated: 2012-10-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
62 participants
OBSERVATIONAL
2012-01-31
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BIS-guided Fluid Management in HD Patients
NCT05272800
The Use of Electrical Bioimpedance to Evaluate Dry Weight in Patients With Chronic Renal Failure in Hemodialysis
NCT03232515
Comparison of Body Hydration State in Hemodialysis Patients
NCT01814254
Bioimpedance as a Tool for Fluid Management in Peritoneal Dialysis (PD) Patients
NCT00801112
Optimal Frequency of Total Body Water Measurements by Bioelectrical Impedance Analysis to Prevent Intradialytic Hypotension
NCT06279156
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients before dialysis treatment
medical Body Composition Analyzer seca 514/515
Current of 100 µA
Deuterium and Sodium Bromide dilution methods
Orally administered to the subject in a solution with 100 ml tap water.
Patients after dialysis treatment
medical Body Composition Analyzer seca 514/515
Current of 100 µA
Deuterium and Sodium Bromide dilution methods
Orally administered to the subject in a solution with 100 ml tap water.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
medical Body Composition Analyzer seca 514/515
Current of 100 µA
Deuterium and Sodium Bromide dilution methods
Orally administered to the subject in a solution with 100 ml tap water.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* gastrointestinal tract illnesses that influence the absorption of substances that are needed for dialysis
* bed-ridden patients patients with clinical relevant hypervolaemia or hypovolaemia
* electrical implant as cardiac pacemaker
* insulin pumps
* pregnancy or breastfeeding period
* subjects who cannot provide an Informed Consent Form (ICF) by themselves
* subjects who might be dependent from the sponsor or the investigation site
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seca GmbH & Co. Kg.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Torsten Slowinski, Dr.
Role: PRINCIPAL_INVESTIGATOR
Charite University, Berlin, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Charité University Medicine Berlin
Berlin, State of Berlin, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BCA-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.